Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex

Clin Pharmacol Ther. 1989 Nov;46(5):494-500. doi: 10.1038/clpt.1989.176.


The anti-human immunodeficiency virus drug zidovudine is metabolized extensively in human beings to the 5'-glucuronide (GAZT) and is cleared rapidly, resulting in a short half-life and the need for frequent dosing. This study explores whether probenecid, which is also metabolized by glucuronidation, reduces zidovudine clearance when zidovudine is administered orally to patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC). The mean zidovudine plasma levels were significantly higher after concurrent administration of probenecid than in its absence, resulting in a twofold increase in the mean AUC, a corresponding decline in the apparent total clearance, and a prolongation in the mean half-life. Similar alterations were observed in GAZT disposition. There was a marked reduction in the urinary excretion ratio of GAZT to zidovudine and a decline in the renal clearance of GAZT after probenecid coadministration. Probenecid inhibits zidovudine glucuronidation and renal excretion of GAZT.

MeSH terms

  • AIDS-Related Complex / metabolism*
  • Acquired Immunodeficiency Syndrome / metabolism*
  • Adult
  • Drug Interactions
  • Drug Therapy, Combination
  • Half-Life
  • Humans
  • Male
  • Middle Aged
  • Probenecid / pharmacokinetics
  • Probenecid / pharmacology*
  • Regression Analysis
  • Zidovudine / analogs & derivatives
  • Zidovudine / blood
  • Zidovudine / pharmacokinetics*
  • Zidovudine / urine


  • Zidovudine
  • 3'-azido-3'-deoxy-5'-O-beta-glucopyranuronosylthymidine
  • Probenecid